# SLIT2

## Overview
SLIT2 is a gene that encodes the protein slit guidance ligand 2, a secreted glycoprotein involved in a variety of biological processes, including axon guidance, neuronal migration, and vascular development. The SLIT2 protein is characterized by its complex structure, which includes leucine-rich repeat (LRR) domains, EGF-like repeats, and a cysteine knot motif, facilitating its interaction with ROBO receptors, particularly ROBO1 and ROBO2 (Morlot2007Structural). This interaction is crucial for the formation of the Slit-Robo signaling complex, which plays a significant role in cellular processes such as cell proliferation, migration, and adhesion (Li2017Slit2). Beyond its developmental roles, SLIT2 is implicated in tumor suppression, often undergoing epigenetic silencing in various cancers, thereby influencing cancer cell migration and invasion (Dickinson2004Epigenetic). The gene's involvement in both normal physiological processes and pathological conditions underscores its potential as a therapeutic target in oncology and regenerative medicine.

## Structure
The SLIT2 protein is a large extracellular protein composed of 1529 amino acids, characterized by several distinct domains. Its structure includes an N-terminal signal peptide, four tandem leucine-rich repeat (LRR) domains, a series of EGF-like repeats, a conserved ALPS spacer (laminin G-like domain), and a C-terminal cysteine knot (CTCK) that serves as a dimerization motif (Liu2018Missense). The LRR domains are crucial for mediating protein-protein interactions, particularly with ROBO receptors, which are part of the Ig superfamily of transmembrane signaling molecules (Morlot2007Structural). The second LRR domain of SLIT2 is specifically involved in binding to the N-terminal Ig domains of ROBO1, facilitating the formation of the Slit-Robo signaling complex (Morlot2007Structural).

The SLIT2 protein undergoes post-translational modifications, including glycosylation, which is evident in the D3 domain (Morlot2007Production). Structural studies have shown that the SLIT2 D3 domain contains six LRR repeats flanked by cysteine-rich capping domains, similar to other secreted LRR proteins (Morlot2007Production). The protein's structure is further stabilized by electrostatic and hydrophobic interactions, which are essential for its function in neuronal and vascular development, as well as in cancer progression (Morlot2007Structural).

## Function
The SLIT2 gene encodes a protein that plays a critical role in axon guidance and neuronal migration during neural development. SLIT2 interacts with the Roundabout 1 (Robo1) receptor, forming a key ligand-receptor interaction that guides axons at the midline, a crucial choice point during embryonic development (Morlot2007Production). The protein is secreted by glial cells and is involved in various cellular processes, including cell proliferation, migration, and adhesion (Li2017Slit2). 

SLIT2 is also implicated in the regulation of endothelial cell proliferation and migration by inhibiting the VEGF-Notch signaling pathway, which is crucial for vascular development and stability (Li2017Slit2). In the context of hematopoietic stem cells, SLIT2 positively regulates their numbers and enhances their repopulation capacity, suggesting its potential as a therapeutic target for expanding stem cells (Waterstrat2016Quantitative). 

In addition to its role in neural and vascular systems, SLIT2 is involved in the morphogenesis of the islets of Langerhans, where it, along with SLIT3, is necessary for maintaining islet structure (Gilbert2021Morphogenesis). SLIT2's functions extend to tumor suppression, where it acts as a midline repellent to guide axonal development and is frequently subject to epigenetic silencing in various cancers (Dickinson2004Epigenetic).

## Clinical Significance
SLIT2, a gene involved in the SLIT/ROBO signaling pathway, plays a significant role in various cancers due to its influence on cell migration and invasion. In breast cancer, SLIT2 frequently undergoes genetic alterations such as promoter methylation and deletion, which are associated with poor prognosis and are particularly prevalent in triple-negative breast cancer (BHATTACHARYA2016Frequent). In colorectal cancer, SLIT2 expression is often reduced due to hypermethylation, which can inhibit cancer cell migration by stabilizing ROBO1 (Jiang2019Targeting). 

In pancreatic cancer, low SLIT2 expression is linked to lymphatic metastasis, and it inhibits the migration and invasion of cancer cells (Jiang2019Targeting). SLIT2 also acts as a tumor suppressor in primary central nervous system lymphoma, where variants in the gene are associated with shorter progression-free and overall survival, suggesting a loss-of-function effect (Kaulen2021Exome). 

SLIT2's role extends to other cancers, including gliomas, where it is frequently inactivated by promoter hypermethylation, indicating its function as a tumor suppressor (Dickinson2004Epigenetic). These findings highlight SLIT2's potential as a target for therapeutic intervention in various malignancies.

## Interactions
SLIT2, a secreted glycoprotein, interacts primarily with ROBO receptors, particularly ROBO1 and ROBO2, to mediate various cellular processes. The interaction between SLIT2 and ROBO1 is facilitated by the binding of the second leucine-rich repeat (LRR) domain of SLIT2 to the first immunoglobulin (Ig) domain of ROBO1. This interaction is characterized by electrostatic and hydrophobic interactions involving conserved residues, which are crucial for the formation of the Slit-Robo signaling complex (Morlot2007Structural). 

SLIT2 also interacts with heparan sulfate/heparin, which enhances its binding affinity to ROBO receptors. This interaction is significant in stabilizing the SLIT2-ROBO1 complex (Morlot2007Structural; Sherchan2020The). In addition to its interactions with ROBO receptors, SLIT2 can bind to other receptors such as PlexinA1, independent of ROBO receptors, influencing cellular processes like actin polymerization and cell migration (Sherchan2020The).

SLIT2-ROBO signaling is involved in various biological processes, including axon guidance, angiogenesis, and tumor metastasis. It has been implicated in inhibiting macropinocytosis in macrophages and cancer cells, affecting nutrient uptake and tumor growth (Bhosle2020SLIT2ROBO1signaling).


## References


[1. (Morlot2007Structural) Cecile Morlot, Nicole M. Thielens, Raimond B. G. Ravelli, Wieger Hemrika, Roland A. Romijn, Piet Gros, Stephen Cusack, and Andrew A. McCarthy. Structural insights into the slit-robo complex. Proceedings of the National Academy of Sciences, 104(38):14923–14928, September 2007. URL: http://dx.doi.org/10.1073/pnas.0705310104, doi:10.1073/pnas.0705310104. This article has 148 citations.](https://doi.org/10.1073/pnas.0705310104)

[2. (Liu2018Missense) Katherine Y. Liu, Jesse D. Sengillo, Gabriel Velez, Ruben Jauregui, Lynn Y. Sakai, Irene H. Maumenee, Alexander G. Bassuk, Vinit B. Mahajan, and Stephen H. Tsang. Missense mutation in slit2 associated with congenital myopia, anisometropia, connective tissue abnormalities, and obesity. Orphanet Journal of Rare Diseases, August 2018. URL: http://dx.doi.org/10.1186/s13023-018-0885-4, doi:10.1186/s13023-018-0885-4. This article has 8 citations and is from a peer-reviewed journal.](https://doi.org/10.1186/s13023-018-0885-4)

[3. (Li2017Slit2) Guo-Jian Li, Yong Yang, Guo-Kai Yang, Jia Wan, Dao-Lei Cui, Zhen-Huan Ma, Ling-Juan Du, and Gui-Min Zhang. Slit2 suppresses endothelial cell proliferation and migration by inhibiting the vegf-notch signaling pathway. Molecular Medicine Reports, 15(4):1981–1988, February 2017. URL: http://dx.doi.org/10.3892/mmr.2017.6240, doi:10.3892/mmr.2017.6240. This article has 37 citations and is from a peer-reviewed journal.](https://doi.org/10.3892/mmr.2017.6240)

[4. (Gilbert2021Morphogenesis) Jennifer M. Gilbert, Melissa T. Adams, Nadav Sharon, Hariharan Jayaraaman, and Barak Blum. Morphogenesis of the islets of langerhans is guided by extraendocrine slit2 and slit3 signals. Molecular and Cellular Biology, March 2021. URL: http://dx.doi.org/10.1128/mcb.00451-20, doi:10.1128/mcb.00451-20. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.00451-20)

[5. (Jiang2019Targeting) Zhengdong Jiang, Gang Liang, Ying Xiao, Tao Qin, Xin Chen, Erxi Wu, Qingyong Ma, and Zheng Wang. Targeting the slit/robo pathway in tumor progression: molecular mechanisms and therapeutic perspectives. Therapeutic Advances in Medical Oncology, January 2019. URL: http://dx.doi.org/10.1177/1758835919855238, doi:10.1177/1758835919855238. This article has 53 citations and is from a peer-reviewed journal.](https://doi.org/10.1177/1758835919855238)

[6. (Dickinson2004Epigenetic) R E Dickinson, A Dallol, I Bieche, D Krex, D Morton, E R Maher, and F Latif. Epigenetic inactivation of slit3 and slit1 genes in human cancers. British Journal of Cancer, 91(12):2071–2078, November 2004. URL: http://dx.doi.org/10.1038/sj.bjc.6602222, doi:10.1038/sj.bjc.6602222. This article has 116 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/sj.bjc.6602222)

[7. (Sherchan2020The) Prativa Sherchan, Zachary D. Travis, Jiping Tang, and John H. Zhang. The potential of slit2 as a therapeutic target for central nervous system disorders. Expert Opinion on Therapeutic Targets, 24(8):805–818, May 2020. URL: http://dx.doi.org/10.1080/14728222.2020.1766445, doi:10.1080/14728222.2020.1766445. This article has 7 citations and is from a peer-reviewed journal.](https://doi.org/10.1080/14728222.2020.1766445)

[8. (Bhosle2020SLIT2ROBO1signaling) Vikrant K. Bhosle, Tapas Mukherjee, Yi-Wei Huang, Sajedabanu Patel, Bo Wen Pang, Guang-Ying Liu, Michael Glogauer, Jane Y. Wu, Dana J. Philpott, Sergio Grinstein, and Lisa A. Robinson. Slit2/robo1-signaling inhibits macropinocytosis by opposing cortical cytoskeletal remodeling. Nature Communications, August 2020. URL: http://dx.doi.org/10.1038/s41467-020-17651-1, doi:10.1038/s41467-020-17651-1. This article has 28 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1038/s41467-020-17651-1)

[9. (BHATTACHARYA2016Frequent) RITTWIKA BHATTACHARYA, NUPUR MUKHERJEE, HEMANTIKA DASGUPTA, MD. SAIMUL ISLAM, NEYAZ ALAM, ANUP ROY, PRIYOBRATA DAS, SUSANTA ROYCHOUDHURY, and CHINMAY KUMAR PANDA. Frequent alterations of slit2–robo1–cdc42 signalling pathway in breast cancer: clinicopathological correlation. Journal of Genetics, 95(3):551–563, September 2016. URL: http://dx.doi.org/10.1007/s12041-016-0678-2, doi:10.1007/s12041-016-0678-2. This article has 10 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s12041-016-0678-2)

[10. (Waterstrat2016Quantitative) Amanda Waterstrat, Kyle Rector, Hartmut Geiger, and Ying Liang. Quantitative trait gene slit2 positively regulates murine hematopoietic stem cell numbers. Scientific Reports, August 2016. URL: http://dx.doi.org/10.1038/srep31412, doi:10.1038/srep31412. This article has 9 citations and is from a peer-reviewed journal.](https://doi.org/10.1038/srep31412)

[11. (Morlot2007Production) Cecile Morlot, Wieger Hemrika, Roland A. Romijn, Piet Gros, Stephen Cusack, and Andrew A. McCarthy. Production of slit2 lrr domains in mammalian cells for structural studies and the structure of human slit2 domain 3. Acta Crystallographica Section D Biological Crystallography, 63(9):961–968, August 2007. URL: http://dx.doi.org/10.1107/s0907444907035470, doi:10.1107/s0907444907035470. This article has 16 citations.](https://doi.org/10.1107/s0907444907035470)

[12. (Kaulen2021Exome) Leon D. Kaulen, E. Zeynep Erson‐Omay, Octavian Henegariu, Philipp Karschnia, Anita Huttner, Murat Günel, and Joachim M. Baehring. Exome sequencing identifies slit2 variants in primary cns lymphoma. British Journal of Haematology, 193(2):375–379, January 2021. URL: http://dx.doi.org/10.1111/bjh.17319, doi:10.1111/bjh.17319. This article has 11 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1111/bjh.17319)